References
- Viyda ADB, Devasagayam TPA. Current status of herbal drugs in India: an overview. J Clin Biochem Nutr 2007;41:1–11
- Chattopadhyay P, Hazarika S, Dhiman S, et al. Vitex negundo inhibits cyclooxygenase-2 inflammatory cytokine-mediated inflammation on carrageenan-induced rat hind paw edema. Pharmaconosy Res 2012;4:134–137
- Sehgal CK, Taneja SC, Dhar KL, Atal CK. 2′-p-hydroxybenzoyl mussaenosidic acid a new iridoid glucoside from Vitex negundo. Phytochemistry 1982;21:363–366
- Vishwanathan AS, Basavaraju R. A review on Vitex negundo L. – a medicinally important plant. EJBS 2010;3:30–42
- Sahaf BZ, Moharramipour S, Meshkatalsadal MH. Fumigant toxicity of essential oil from Vitex pseudo-negundo against Tribalism castaneum (Herbst) and Sitophilus oryzae (L.). J Asia Pacific Entamology 1982;4:175–179
- Singh V, Dayal R, Bartley J. Volatile constituents of Vitex negundo leaves. Planta medica 1999;65:580–585
- Azhar UH, Malik A, Anis I, et al. Enzyme inhibiting lignans from Vitex negundo. Chem Pharm Bull 2004;52:1269–1272
- Guide for the Care and Use of Laboratory Animals. NIH Publication No. 85-23, Revised 1985
- OECD. Test No: 402, Acute dermal toxicity. Section 2. 402. Paris: OECD Publishing; 1987:1–3
- OECD. Test No: 434, Acute dermal toxicity – fixed dose procedure Section 20 to 34. 434. Paris: OECD Publishing; 2004:4–5
- OECD. Test No: 411, Subchronic dermal toxicity: 90-day study. Section2. 411. Paris: OECD Publishing; 1981:5–9
- Khokra SL, Prakash O, Jain S, et al. Essential oil composition and antibacterial studies of Vitex negundo Linn. extracts. Indian J Pharm Sci 2006;7:45–55
- Tandon VR, Gupta RK. Vitex negundo Linn (VN) leaf extract as an adjuvant therapy to standard anti-inflammatory drugs. Ind J Med Res 2006;124:303–308
- Haq AU, Malik A, Anis I, et al. Enzyme inhibiting lignans from Vitex negundo. Chem Pharm Bull 2004;52:1269–1272